SPYRE THERAPEUTICS, INC. Derivative Liability, Current
SPYRE THERAPEUTICS, INC. (SYRE) had Derivative Liability, Current of $31.35 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:DerivativeLiabilitiesCurrent · last filed 2026-08-04
- 2026-06-30: Derivative Liability, Current $31.35M.
- 2026-03-31: Derivative Liability, Current $50.26M.
- 2025-12-31: Derivative Liability, Current $22.82M.
- 2025-09-30: Derivative Liability, Current $11.02M.
| Period end | Derivative Liability, Current |
|---|---|
| 2026-06-30 | $31.35M 10-Q · filed 2026-08-04 |
| 2026-03-31 | $50.26M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $22.82M 10-Q · filed 2026-08-04 |
| 2025-09-30 | $11.02M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $59.90M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $42.81M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $25.08M 10-K · filed 2026-02-19 |
| 2024-09-30 | $24.74M 10-Q/A · filed 2024-11-18 |
| 2024-06-30 | $2.64M 10-Q/A · filed 2024-11-18 |
| 2024-03-31 | $2.59M 10-Q/A · filed 2024-11-18 |
| 2023-12-31 | $1.39M 10-K · filed 2025-02-27 |
| 2023-09-30 | $7.51M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $164.38M 10-Q · filed 2023-08-11 |
| 2022-12-31 | $0.00 10-K/A · filed 2024-11-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |